Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2025 · 10-Q
Revenue—
Net Income-$873.47K-$873.47KN/M vs Q3 2024 EPS Diluted-$1.81-$1.81N/M vs Q3 2024 Operating Income-$895,130N/M Operating Cash Flowderived-$1,646,689N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end